uploads/65489_Trinity_AMR_Hero (2).jpg
Presented with
Untitled-(1350-x-1080-px)-(2).jpg

How can data and analytics reduce the impact of antimicrobial resistance and bacterial infections in low- and middle-income communities?

The Trinity Challenge on Antimicrobial Resistance

Closed

Submissions are closed

Timeline

  • Applications Open

    November 14, 2023 9:00am EST
  • Solution Deadline

    November 14, 2023 9:00am EST
  • Reviews

    March 28, 2024 11:59pm EDT
  • First Round Judging

    April 12, 2024 1:00pm EDT
  • Second Round Judging

    May 12, 2024 11:59pm EDT
  • Winner Announcement

    June 6, 2024 12:00pm EDT

Challenge Overview

Antimicrobial resistance - which for the purpose of this Challenge, refers specifically to resistance of bacteria to antibiotics - is a One Health crisis threatening health, food, and environmental security. Current estimates show that the deaths of 4.95 million people each year are associated with antimicrobial resistance, 1.27 million of which are directly attributable to resistance to antibiotics. That death toll is estimated to increase to 10 million per year by 2050. The loss of functioning antibiotics increases our risk from common medical procedures such as surgery, cancer care, and treatment of everyday infections. If left unchecked, antimicrobial resistance will push 24 million people into extreme poverty by 2030, and result in a loss of $13 billion in livestock value per year. 

Although national action plans have been drawn up to mitigate antimicrobial resistance, investment in research and development is being reinvigorated, and support for laboratory infrastructure in some low-income countries has contributed to increased surveillance, much remains to be done. Our current understanding of antimicrobial resistance, antibiotic use, access, and quality, comes almost exclusively from high-income country hospital and industry settings. Community-level data across the One Health spectrum in low- and middle-income countries (LMICs) is a major untouched gap.

We need bold thinking, meaningful collaboration and committed action to fill this gap. By harnessing the power of data and technology at the community level - where the majority of antibiotics are used - we can better understand the problem and take action to protect people, animals, and the environment.

The Trinity Challenge on Antimicrobial Resistance seeks solutions which fall into one or more of the following Challenge Objectives:  

  • Innovation to identify new sources of data, collection, and analysis

  • Integration of existing and novel data sets with citizen-related data (CRD)

  • Implementation of more effective policy and action on antimicrobial resistance by using these tools

Solutions might respond to this One Health crisis by, for example: 

  • Developing new forms of community surveillance for antimicrobial resistance

  • Delivering sustainable access to effective antimicrobials 

  • Developing (or updating) more accurate estimates of bacterial disease and antimicrobial resistance burden

  • Creating greater understanding of community transmission and drivers of antimicrobial resistance in humans, animals, and food production systems 

  • Informing and influencing antimicrobial resistance One Health policy decision making  

  • Countering the dissemination of substandard and falsified antimicrobials for bacterial infection 

  • Improving farm biosafety and environmental security

For guidance on some of the key questions your solution might seek to address, please refer to our Sample Questions.

Glossary of Key Terms

If you are using any key terminology throughout your challenge description, it can be helpful to define these terms for potential applicants to increase clarity. 

  • Citizen-related data (CRD): Data based in the community, which includes health and non-clinical data, such as mobility and climatic, and behavioral data, in addition to that which relates to the food chain (farms and sales) etc.

  • Community-level data: Data that is collected outside of hospitals and other formal healthcare facilities and large-scale food production plants

  • Low- and middle-income countries (LMICs): Countries with a Gross National Income (GNI) less than $13,845 per capita as defined by the World Bank. These include low-income, lower middle-income countries, middle-income countries, and upper middle-income countries

  • One Health: Human, animal, and environmental health

  • Technology: The application of science and evidence-based knowledge to the practical aims of human life. We welcome solutions that are using apps, SMS technology, software, AI, robots, drones, blockchain, and virtual reality. We also welcome solutions that are leveraging traditional, ancestral, and natural technologies, and knowledge systems

 

Prize Eligibility

Prize Funding

Across the Challenge Objectives (Innovation, Integration, Implementation), we seek to identify a transformative solution to win a grand prize award of up to £1 million. Additional prize funding will be allocated to further winning submissions. 

We expect that one or more collaborators from our Challenge network of members will offer mentorship to the winning solutions and we anticipate that awardees will be connected with post-award innovation and monitoring support. The member list of the inaugural Challenge in 2020 can be viewed here.

The exact amount of the award for each winner will depend on the solution’s needs for development, deployment and scaling over the next three years. Following the application stage, shortlisted Challenge finalists will be asked to provide more detailed plans to inform award funding decisions. 

Prize funding awards will be contractually binding between applicants and the Trinity Challenge and must be used to develop the solutions and further the aims of The Trinity Challenge on Antimicrobial Resistance.

Other awards may be made at the discretion of the Judges (e.g., honorable mentions for solutions outstandingly meeting some criteria).

Prize Eligibility

The Trinity Challenge welcomes submissions in English, from anyone, anywhere in the world, including previous applicants. Applicants from LMICs are especially welcome. In addition to offering prize funding, the Trinity Challenge will aim to support winning solutions by enabling collaborations with its Challenge network of members.

Within their submission, applicants must outline how their solution provides a public benefit that would be globally accessible under fair, reasonable and non-discriminatory terms.

The Trinity Challenge on Antimicrobial Resistance is focused exclusively on finding solutions in LMICs. 

While submissions are welcomed from organizations based in high-income countries (HICs), in keeping with the focus of this Challenge and the vision of The Trinity Challenge, applicants from HICs must demonstrate bona fide partnerships with LMIC researchers or organizations as part of the challenge team. This must also be reflected in the flow of funds in the budget proposal and justification. Furthermore, data must be relevant to, or collected from, LMICs, and not HICs.

Government agencies or their foundations cannot apply to the Challenge. Individuals from within these entities, but not the entity itself, may apply as a part of the solution team.

While submissions are welcome from anyone, the following eligibility criteria must be met in order to receive prize funding.

Prize funding is available to any of the following entities:

  • Teams or institutions, provided that they will create or appoint a legally registered organization in the home jurisdiction with a bank account to receive prize funding 

  • Organizations, in any form, that are legally registered in their home jurisdiction with a bank account registered to that organization

  • A consortium of the above, provided that a lead organization and lead individual is identified

  • The Trinity Challenge may require that a prize winner appoints a fiscal sponsor to receive and administer any award funds on their behalf

Prize funding will not be awarded to any of the following:

  • Individuals or those under 18 years of age

  • Applicants that focus on interventions in HICs 

  • Any donor that has made a financial contribution to The Trinity Challenge prize fund

  • Government agencies or their foundations

  • Any applicant that fails the Trinity Challenge due diligence checks 

  • Any applicant that does not agree to the Trinity Challenge Award Agreement

  • A submission from an organization operating in a sanctioned country (see Terms of Service)

  • For-profit companies that fulfill (or are controlled by a for-profit group that fulfills) any two of the following conditions:

    • Annual revenue/turnover in excess of £50 million per year

    • Balance sheet net assets in excess of £20 million

    • Average monthly FTE employees in excess of 250

The Trinity Challenge on Antimicrobial Resistance supports the FAIR principles, CARE principles, and the principle of open-access data and encourages applications from solutions teams that reflect a wide range of perspectives and life experiences. 

FAQs

Table of Contents

About The Trinity Challenge on Antimicrobial Resistance

What is The Trinity Challenge?

Why focus on the pandemic of antimicrobial resistance?

Why focus on data from communities in low- and middle-income countries (“LMICs”)?

Why focus on data and analytics?

Who are the Challenge’s collaborators?

Solution Submissions & Winner Selection

Why should I apply to the Challenge?

Who is eligible to apply to the Challenge?

Can I apply if I have a data/analytics solution that is not currently focused on AMR?

How should teams be composed?

Can the members of the Challenge network apply to the Challenge?

What are the submission requirements?

What is the award structure and the maximum funding?

What can I use the award for?

What are budget requirements and limitations?

What costs can I include in our budget?

How will the Challenge be judged?

When will the finalists and winners be announced?

Is existing open source software permitted?

Are submissions with existing code permitted?

Legal

Who will own the intellectual property of the insights, submissions and data from the Challenge?

Will my solution be made public?

How do the winners have to conduct their work? Are there any restrictions?

Who decides the terms of agreement between applicants and collaborators?

About The Trinity Challenge on Antimicrobial Resistance

What is The Trinity Challenge? 

The Trinity Challenge (TTC) is a charity supporting the creation of data-driven solutions to help protect against global health threats. 

We believe data and analytics hold the key to building effective, affordable, and scalable solutions to current and future pandemics and health emergencies. We support data-driven solutions that will help the world prepare for and respond to global outbreaks and health emergencies. We’re committed to working with governments, individuals and organizations across the world, to help improve our resilience against current and future threats to global health.

Why focus on the pandemic of antimicrobial resistance?

Antimicrobial resistance, which for the purposes of this Challenge relates specifically to antibiotic resistance in bacteria, is a global security threat, impacting human, animal, and environmental health (often referred to as One Health). Losing effective antibiotics to prevent or treat bacterial infections increases mortality from previously treatable, common infections such as pneumonia, urine infections and meningitis, and increases the risk of everyday medical interventions such as surgery and cancer care. Our food security requires healthy animals and is also adversely impacted by environmental contamination, with antibiotics from the pharmaceutical industry and unsafe water and sanitation systems causing increased levels of antimicrobial resistance in environmental bacteria which enter the food chain. While much of the world’s attention is on the next pandemic akin to COVID-19, human health and wellbeing is inescapably linked to antimicrobial resistance. For this reason, The Trinity Challenge has chosen it as the focus of the Challenge.

Why focus on data from communities in low- and middle-income countries (“LMICs”)?

Our current understanding of data relating to antimicrobial resistance comes predominantly from laboratory-isolated bacteria from hospitalized patients in high-income countries, or via data from food industries. Major data gaps exist in LMICs and especially from community settings. This is despite the vast majority of antibiotics being used in exactly these settings, i.e. out-of-hospital, on farms, etc. 

Advances in analytics and new sources of data proved a critical factor in improving surveillance and our understanding of the COVID-19 pandemic, for example: whole genome sequencing of wastewater was able to predict community-level transmission of SARS-CoV-2, enabling organization of resources for most impact. The Trinity Challenge believes that equal attention to community-level data for antimicrobial resistance will bring fresh insights and capability to implement more focused policy and action.

Why focus on data and analytics?

Major gaps in data related to antimicrobial resistance exist in LMICs, especially from community settings. This is despite the vast majority of antibiotics being used in exactly these settings. The Challenge aims to promote innovation in finding new data sources and integration of data, steering clear of incomplete and siloed information. The Trinity Challenge encourages novel analytics and technology to derive evidence-based knowledge, and drive more effective policy and action. 

Who are the Challenge’s collaborators?

The Challenge is supported by a dedicated group of collaborators who offer mentoring and other resources to solutions. Collaborators are announced during the course of the Challenge. Examples of the types of organizations that may be involved can be found in the list of inaugural Challenge Members here.

In your submission, you can highlight specific organizations you wish to work with or indicate a broader expertise that would benefit your solution. Organizations are not restricted to confirmed collaborators - you can name anyone, from the inaugural Challenge or elsewhere.

Following the submission deadline, The Trinity Challenge will aim to facilitate connections with organizations that might best support your objectives - either through confirmed collaborators or the wider Challenge network.

If a collaborator expresses an interest in working with an applicant, The Trinity Challenge will reach out to you to set up a discussion.

Working with a collaborator is not a condition of applying.

Solution Submissions & Winner Selection

Why should I apply to the Challenge?

Your work for the public good might benefit in three key areas through the Challenge:

  1. Public recognition in line with our aspiration to further the public good through data and analytics. The Trinity Challenge will promote the Challenge and its finalists with an ongoing and extensive outreach through its own communication channels as well as the public and social media of the Challenge network of members and partners. This recognition will coincide with a significant year in the struggle against antimicrobial resistance on the world stage, including a high-level meeting at the United Nations General Assembly in September 2024.

  2. Unparalleled support by global leaders from the private, academic and public sectors. A core asset and distinguishing factor of the Challenge is the support of its collaborators - a cross-sector group of leading institutions in their respective fields, committed to supporting solutions with the resources required to make a positive and lasting impact for the public good.

  3. Significant awards. The Trinity Challenge will award the best solutions with prizes from its award pool. The selection of winners and distribution of awards from that pool will happen at the discretion of an independent panel of expert judges representing various disciplines and backgrounds, through a quality-controlled, fair and transparent process.

Who is eligible to apply to the Challenge?

Please refer to the Challenge’s ‘Prize Eligibility’ tab.

Can I apply if I have a data/analytics solution that is not currently focused on AMR? 

Yes! A key focus of the Trinity Challenge on Antimicrobial Resistance is to identify new sources of data, collection, and analysis. If you have an existing solution focused on community-level health, environmental, agricultural, or other relevant data & analytics and a clear idea on how this could be applied to better understand or address the problem of antimicrobial resistance, we encourage you to apply. You may wish to consider how expertise in antimicrobial resistance could help you deliver a new AMR-focussed version of your solution, and can identify potential collaborators in your application.

How should teams be composed?

The Trinity Challenge is committed to representing the global community it serves by embracing diversity. All applicants are encouraged to participate and solutions are welcomed from teams that reflect a wide range of perspectives and life experiences through their partnerships, community engagement, or team members. To help the Trinity Challenge achieve this goal, applicants are encouraged to draw attention to their team's composition in the "More About Your Team" section of the application form.

Can the members of the Challenge network apply to the Challenge?

Members are invited to make submissions if the eligibility criteria is met, however Members that have contributed into the prize fund are ineligible to win. Members may be part of the reviewing or judging process where no conflict of interest is identified.

What are the submission requirements? 

Please refer to the Challenge’s ‘Prize Eligibility’ tab.

What is the award structure and the maximum funding?

Please refer to the Challenge’s ‘Prize Eligibility’ tab. The maximum funding is £1 million. The Trinity Challenge can increase or decrease this amount at their discretion. 

What can I use the award for?

If you are selected as a winner of the Challenge, you may only use the award to further your solution as specified in your submission. This can materialize in a variety of ways: hiring resources to support development or deployment of your solution, purchasing software licenses or computing credits to support your submission, purchasing equipment necessary for the deployment of your solution, etc. 

You may not use the award for personal expenses. You will need to maintain records of your expenditure and report back to us on a regular basis. 

What are budget requirements and limitations?

You are required to submit a high level 1 year and 3 year budget that includes what is needed to fully develop your solution if you are awarded £1 million and how you would adjust your project if you received £500,000. If you are shortlisted as a finalist, you may be required to provide further details on your expenses and timing requirements. 

What costs can I include in our budget?

You can include direct costs and, to a reasonable level, real indirect and true overhead costs. For clarity, the Trinity Challenge defines these 3 categories in the following ways:

  • Direct Costs

    • Definition: Costs relating to the delivery of the solution, which would not be incurred if the solution was not being run.

    • Budget restrictions: None - budgeted in full.

    • Examples*: Staff salaries/fees, contractor fees, travel, accommodation, equipment/hardware (project specific), IT/software (project specific), licences, supplies, legal, insurance (project specific)

  • Real Indirect Costs

    • Definition: Costs relating to the support of a group of projects, of which your solution may be one within your organization, which would not be incurred if projects were not being run.

    • Budget restrictions: Apportioned according to the share of resource that is required by the solution, without a cap.

    • Examples*: Project specific finance manager, equipment/hardware (project shared), IT/software (project shared), Monitoring, Evaluation, Accounting and Learning (MEAL) analysts

  • True Overhead Costs
    • Definition: Costs relating to organisational maintenance, which would still be incurred if projects were not being run.
    • Budget restrictions:Apportioned according to the share of resource that is required by the solution, with a maximum cap of 10% of the total budget.
    • Examples*: HR department costs, accounting software, board governance costs, building/maintenance costs, organizational finance and procurement support.

*Examples are not exhaustive.

How will the Challenge be judged?

Please refer to the Challenge’s ‘Judges & Criteria’ tab. 

When will the finalists and winners be announced? 

Finalists and unsuccessful applicants will be contacted in late April / early May 2024.

The winners will be announced publicly in a ceremony in June 2024.

Is existing open source software permitted?

You are free to use and build on existing open source software and projects. Adherence to any legal requirements remains the sole responsibility of the solution’s team.

Are submissions with existing code permitted?

You are free to use existing code and content, and build on existing and on-going work to submit the best insights possible. Adherence to any legal requirements remains the sole responsibility of the solution’s team.

Legal

Who will own the intellectual property of the insights, submissions and data from the Challenge?

  • Any intellectual property that existed prior to the creation of any solution (“Background IPR”) remains the property of its respective owners, and you are responsible for ensuring that you have the right to incorporate any such property into your solution and any potential project resulting from an award through the Challenge.

  • Any new intellectual property created during the course of the Challenge (“Foreground IPR”), from submission to delivery, will be owned by you. If a solution is managed jointly by more than one organization, they are responsible for allocating these ownership rights amongst themselves. 

  • Solutions must create a public benefit that would be globally accessible under fair, reasonable and non-discriminatory terms. As a minimum, winners of the Challenge therefore may need to release enough Foreground IPR into the public domain to allow this.

Will my solution be made public?

Solutions will be posted publicly on the Challenge’s ‘Solutions’ tab; this will include answers to questions that aim to provide an overview of the problem, a summary of the solution, and the team. However any question in the submission that is marked with either “For Judge Use Only” or “For Solve Use Only” will be kept confidential. 

How do the winners have to conduct their work? Are there any restrictions?

Winners can define their working mode and norms. However, all collaborative development will have to follow the Challenge guidelines outlined above. It will be assumed that any winner or Member sharing data within The Trinity Challenge does so in accordance with relevant and applicable legal and regulatory standards and obligations including, but not limited to, confidentiality, data protection and intellectual property. Members will collaborate with the winners, and in some circumstances, provide access to data under their own data governance arrangements. Teams must adhere to these policies and processes. Adherence to any legal requirements remains the sole responsibility of the winner/collaborators.

Who decides the terms of agreement between applicants and collaborators?

The terms of any agreement are discussed, decided upon, and contracted between you and the collaborator individually. These terms need to respect the guidelines of the Challenge, which include:

  • Adhering to the principles of respect, integrity and transparency in relation to the Trinity Challenge and the Challenge

  • Promoting the values of open collaboration, open data (to the extent possible) and making the benefits of the Challenge global and accessible

  • Respecting and abiding by the information governance arrangements and procedures of collaborators

Judging Criteria

  • Potential for Impact: The planned solution implementation has the potential to impact the intended population.
  • Feasibility: The team has a realistic, practical plan for implementing the solution, it is feasible in the given context, and the team has a reasonable plan for operational sustainability and measurable results that can be proven to work.
  • Innovative Approach: The solution includes a new technology, a new application of data, digital tools and/or analytics, a new policy model, or a new process for solving the Challenge.
  • Inclusive Human-Centered Design: Inclusive and equitable outcomes are considered in the design, implementation, and internal operations of the solution.
  • Scalability: The solution has a plan for equitable viability and the potential to be scaled to affect the lives of more people in low- and middle-income countries.
  • Proximate Leadership: The solution is led by a visionary entrepreneur, innovator, or team who has deep understanding of the communities they serve and the problem they are trying to solve, expertise to develop and implement solutions, and the ability to adapt and respond to fe
  • Technical Feasibility: The applicant has provided convincing evidence that the data/analytics underpinning the solution have been built and function as they claim they do, even if only proof-of-concept.

Solutions

Selected

AMRoots: AMR in small-scale farming communities

By Helen McIlleron
Helen McIlleron Tasha Koch Mary-Ann Davies Craig Kinnear Rachel Wynberg Lubbe Wiesner
Selected

AMRSense: Empowering Communities with a Proactive OneHealth Ecosystem

By Tavpritesh Sethi
Tavpritesh Sethi Nikhil Doegar Harpreet Singh Tikesh Bisen Kritika Gupta
Selected

OASIS: OneHealth Antimicrobial Stewardship for Informal Health Systems

By Meenakshi Gautham
Meenakshi Gautham Sujay Santra Chang Ho Yoon Indranil Samanta Kathryn Holt Sanghita Bhattacharyya Catherine Goodman Priya Balasubramaniam
Selected

Farm2Vet: Combatting AMR on the Farm Frontier

By Giang Phi
Giang Phi Helen Nguyen Kok-Seng Wong Khoa D. Doan
Finalist

SafeMeat

By Grace Chitau
Grace Chitau
Finalist

CHAMP: Community Health Antimicrobial Resistance Platform

By Pranav Savanur
Pranav Savanur Ruchit Nagar Mohammad Sarfarazul Ambiya Mohammed Shahnawaz Hemant Sharma
Finalist

Community Surveillance and AI Solutions for AMR Reduction in Kenya

By Abdullah Kanneh
Abdullah  Kanneh
Finalist

AMR in urban informal settlements of Fiji: insights for policy action

By Brett Davis
Brett Davis
Submitted

Deciphering the nexus of AMR in One Health using Digital Innovation

By Emily Sheldon
Emily Sheldon Harry Akligoh Samuel Sakyi Alexander Kwakye
Submitted

1Mpacto AZap: AI-Driven Antimicrobial Resistance Mapping in Brazil

By João Marcelo Occhiucci
João Marcelo Occhiucci David Souza Jose Belizario Vanessa Lima Souza Vilar Humberto Garay-Malpartida
Submitted

CitiSafe

By Nyamizi Maganga
Nyamizi Maganga
Submitted

VetCare360: Advancing Antimicrobial Resistance Solutions

By RITHA PASKALI
RITHA PASKALI
Submitted

AMR Alert System for real-time surveillance of AMR (AMR ALS Thailand)

By Pimlapas Leekitcharoenphon
Pimlapas Leekitcharoenphon Thidathip Wongsurawat Piroon Jenjaroenpun Achiraya Siriphap Nuvee Prapasarakul
Submitted

Equitable AI use to reduce the impact of AMR and bacterial infections

By Geraldine Mbagwu
Geraldine Mbagwu
Submitted

Saving lives by optimizing the MDA vs AMR tradeoff

By Seth Blumberg
Seth Blumberg Sani OUSMANE Thumbi Mwangi Ashley Styczynski Thuy Doan Gwen Knight Thomas Lietman Kieran O'Brien

Meet the Judges

Co-chairs

Mark Dybul

Mark Dybul

Center for Global Health Practice and Impact, Georgetown University Medical Center, Professor of Medicine, Chief Strategy Officer
Divleen Jeji

Divleen Jeji

Google Health, India Lead

Judges

Patipat Susumpow

Patipat Susumpow

Opendream, Managing Director
Mark Dybul

Mark Dybul

Center for Global Health Practice and Impact, Georgetown University Medical Center, Professor of Medicine, Chief Strategy Officer
Divleen Jeji

Divleen Jeji

Google Health, India Lead
Kat Esser

Kat Esser

Amazon, Principal, Health Equity Strategy & Innovation
Mirfin Mpundu

Mirfin Mpundu

ReAct Africa, Executive Director
Lesley-Anne  Long

Lesley-Anne Long

Wonderfuture, CEO
Karen  Bett

Karen Bett

Global Partnership for Sustainable Development Data, Senior Policy Manager, Data Equity & Inclusion
Peiling  Yap

Peiling Yap

HealthAI - The Global Agency for Responsible AI in Health, Chief Scientist
Erick  Venant

Erick Venant

Roll Back Antimicrobial Resistance Initiative (RBA Initiative), Founder
Akhil  Bansal

Akhil Bansal

AMR Funding Circle, Founder
Sumi  Robson

Sumi Robson

Wellcome Trust, Senior Research Manager
Metuge  Alain

Metuge Alain

Reach Out Cameroon, Head of Health Department
Yewande  Alimi

Yewande Alimi

Africa CDC, One Health Unit Lead
Aqil  Jeenah

Aqil Jeenah

McKinsey & Company, Management Consultant | Veterinarian
Chris Butler

Chris Butler

Nuffield Department of Primary Care Health Sciences, University of Oxford, Clinical Director, Primary Care Clinical Trials Unit, University of Oxford
Elizabeth  Ashley

Elizabeth Ashley

Lao-Oxford-Mahosot Hospital-Wellcome Trust Research Unit, Director
Glenda Gray

Glenda Gray

South African Medical Research Council, President and CEO
James Anderson

James Anderson

IFPMA, Executive Director, Global Health
Timothy Walsh

Timothy Walsh

Ineos Oxford Institute, Microbiologist
Toby Leslie

Toby Leslie

The Fleming Fund / Mott MacDonald, Global Technical Lead